BioCardia (NASDAQ:BCDA) Stock Price Up 1% – Still a Buy?

BioCardia, Inc. (NASDAQ:BCDA)’s stock price rose 1% during mid-day trading on Thursday. The company traded as high as $1.0450 and last traded at $1.02. 205,872 shares were traded during mid-day trading, a decline of 43% from the average daily volume of 358,596 shares. The stock had previously closed at $1.01.

Analyst Upgrades and Downgrades

BCDA has been the topic of several recent research reports. Zacks Research upgraded BioCardia from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. Wall Street Zen raised shares of BioCardia from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. HC Wainwright reiterated a “buy” rating on shares of BioCardia in a research note on Monday, August 24th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of BioCardia in a report on Friday, July 17th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, BioCardia currently has an average rating of “Hold” and a consensus price target of $25.00.

BioCardia Stock Up 1.0%

The firm has a market capitalization of $15.44 million, a PE ratio of -1.59 and a beta of 0.62. The stock has a 50-day moving average price of $1.02 and a 200 day moving average price of $1.04.

BioCardia (NASDAQ:BCDA) last announced its earnings results on Wednesday, August 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.05. As a group, equities analysts predict that BioCardia, Inc. will post -0.71 earnings per share for the current fiscal year.

About BioCardia

BioCardia, Inc is a biotechnology company developing regenerative medicine therapies for cardiovascular diseases. The company focuses on cell-based treatments intended to repair or improve damaged heart tissue and restore cardiac function in patients with serious cardiovascular conditions.

BioCardia’s portfolio includes the investigational CardiAMP Cell Therapy System, which uses a patient’s own bone marrow-derived cells and is being evaluated for conditions such as ischemic heart failure and chronic myocardial ischemia.